A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Inclusion Criteria:

-Has either not received lipid-lowering therapy (LLT) or has not received certain LLTs within a specified time period prior to the study.

Exclusion Criteria:

• Has a history of homozygous familial hypercholesterolemia (FH), compoundheterozygous FH, or double heterozygous FH.

• Had a heart failure hospitalization within 3 months before Screening.

• Is unwilling to take a statin, and/or has a history of statin-associated musclesymptoms or other statin-related AEs to any statin and dose, and/or is known to beintolerant to 1 or more statins.

• Has a history of any of the following conditions: (1) Myopathy, myositis,rhabdomyolysis, or unexplained muscle pain; (2) Muscular or neuromuscular disease; (3) Neuropathy, fibromyalgia, or chronic pain; or (4) Has a personal or familyhistory of hereditary muscular disorders.

• Has active or chronic hepatobiliary or hepatic disease.

• Has known human immunodeficiency virus (HIV) infection.

• Is undergoing or previously underwent an LDL-C apheresis program within 3 monthsbefore Screening or plans to initiate an LDL-C apheresis program.

• Has received any medication that may interact with rosuvastatin within 5 half-livesprior to Screening or is planning to initiate such treatment.